{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:58:40Z","timestamp":1790481520707,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    mTOR inhibitors including everolimus and temsirolimus have been approved by US FDA for treatment of clear cell renal cell carcinoma (ccRCC) in clinic. However, resistance to these drugs has been inevitable and the underlying mechanism remains poorly understood. Histone modifier ZMYND8 paradoxically acts as a transcription coactivator or corepressor. Here we show that SPOP, a CULLIN3-RING E3 ubiquitin ligase (CRL) substrate-binding protein that is often overexpressed in ccRCC in patients, promotes K63-linked polyubiquitination of ZMYND8 at lysine 398, which inhibits ZMYND8 to form phase separation compartments and drives the formation of ZMYND8-ZHX2 transactivation complex, resulting in aberrant\n                    <jats:italic>NEK7<\/jats:italic>\n                    kinase gene transcription, alternative activation of p70S6K, and mTOR inhibitor-resistant cell growth. Inhibition of either SPOP or NEK7 increases ccRCC cell sensitivity to mTOR inhibitor. Treatment with a NEK7 proteolysis-targeting chimera (PROTAC) effectively inhibits aberrant p70S6K activation and overcame everolimus resistance in ccRCC cells in vitro and in mice. Our findings uncover a function switch of ZMYND8 driven by overexpressed SPOP as a key mechanism that causes mTOR inhibitor resistance and nominate NEK7 as a potential target of thwarting mTOR inhibitor resistance in ccRCC.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-77043-9","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:07:05Z","timestamp":1787648825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Bo","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5024-2841","authenticated-orcid":false,"given":"Qi-You","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-2385","authenticated-orcid":false,"given":"Dejie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-5634","authenticated-orcid":false,"given":"Lianxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-7697","authenticated-orcid":false,"given":"Yicheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-3835","authenticated-orcid":false,"given":"Chengheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-6413","authenticated-orcid":false,"given":"Haojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"77043_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose, T. L. & Kim, W. Y. Renal cell carcinoma: a review. JAMA 332, 1001\u20131010 (2024).","journal-title":"JAMA"},{"key":"77043_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"77043_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N. Engl. J. Med. 391, 710\u2013721 (2024).","journal-title":"N. Engl. J. Med."},{"key":"77043_CR4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.molcel.2016.06.035","volume":"63","author":"N Li","year":"2016","unstructured":"Li, N. et al. ZMYND8 reads the dual histone mark H3K4me1-H3K14ac to antagonize the expression of metastasis-linked genes. Mol. Cell 63, 470\u2013484 (2016).","journal-title":"Mol. Cell"},{"key":"77043_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cell.2016.02.064","volume":"165","author":"H Shen","year":"2016","unstructured":"Shen, H. et al. Suppression of enhancer overactivation by a RACK7-histone demethylase complex. Cell 165, 331\u2013342 (2016).","journal-title":"Cell"},{"key":"77043_CR6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1172\/JCI95089","volume":"128","author":"Y Chen","year":"2018","unstructured":"Chen, Y. et al. ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis. J. Clin. Invest. 128, 1937\u20131955 (2018).","journal-title":"J. Clin. Invest."},{"key":"77043_CR7","doi-asserted-by":"publisher","first-page":"e2019052118","DOI":"10.1073\/pnas.2019052118","volume":"118","author":"B Tang","year":"2021","unstructured":"Tang, B. et al. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Proc. Natl. Acad. Sci. USA 118, e2019052118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77043_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","volume":"23","author":"P Zhang","year":"2017","unstructured":"Zhang, P. et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat. Med. 23, 1055\u20131062 (2017).","journal-title":"Nat. Med."},{"key":"77043_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.molcel.2015.07.025","volume":"59","author":"J An","year":"2015","unstructured":"An, J. et al. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 59, 904\u2013916 (2015).","journal-title":"Mol. Cell"},{"key":"77043_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.celrep.2014.01.013","volume":"6","author":"J An","year":"2014","unstructured":"An, J., Wang, C., Deng, Y., Yu, L. & Huang, H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 6, 657\u2013669 (2014).","journal-title":"Cell Rep."},{"key":"77043_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102795","volume":"56","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. SPOP promotes ubiquitination and degradation of LATS1 to enhance kidney cancer progression. EBioMedicine 56, 102795 (2020).","journal-title":"EBioMedicine"},{"key":"77043_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/nar\/gkw814","volume":"45","author":"K Zhu","year":"2017","unstructured":"Zhu, K. et al. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing. Nucleic Acids Res. 45, 92\u2013105 (2017).","journal-title":"Nucleic Acids Res."},{"key":"77043_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ccr.2014.02.007","volume":"25","author":"G Li","year":"2014","unstructured":"Li, G. et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 25, 455\u2013468 (2014).","journal-title":"Cancer Cell"},{"key":"77043_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41585-020-0314-z","volume":"17","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. The diverse roles of SPOP in prostate cancer and kidney cancer. Nat. Rev. Urol. 17, 339\u2013350 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"77043_CR15","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/cncr.22677","volume":"109","author":"AJ Pantuck","year":"2007","unstructured":"Pantuck, A. J. et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109, 2257\u20132267 (2007).","journal-title":"Cancer"},{"key":"77043_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289\u20131300 (2021).","journal-title":"N. Engl. J. Med."},{"key":"77043_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2016.08.003","volume":"30","author":"ZQ Guo","year":"2016","unstructured":"Guo, Z. Q. et al. Small-molecule targeting of E3 ligase adaptor SPOP in kidney cancer. Cancer Cell 30, 474\u2013484 (2016).","journal-title":"Cancer Cell"},{"key":"77043_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.molcel.2009.09.022","volume":"36","author":"M Zhuang","year":"2009","unstructured":"Zhuang, M. et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 36, 39\u201350 (2009).","journal-title":"Mol. Cell"},{"key":"77043_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.molcel.2022.12.033","volume":"83","author":"MJ Cuneo","year":"2023","unstructured":"Cuneo, M. J., O\u2019Flynn, B. G., Lo, Y. H., Sabri, N. & Mittag, T. Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation. Mol. Cell 83, 731\u2013745.e734 (2023).","journal-title":"Mol. Cell"},{"key":"77043_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26864-x","volume":"12","author":"P Jia","year":"2021","unstructured":"Jia, P. et al. ZMYND8 mediated liquid condensates spatiotemporally decommission the latent super-enhancers during macrophage polarization. Nat. Commun. 12, 6535 (2021).","journal-title":"Nat. Commun."},{"key":"77043_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41594-020-0394-8","volume":"27","author":"X Han","year":"2020","unstructured":"Han, X. et al. Roles of the BRD4 short isoform in phase separation and active gene transcription. Nat. Struct. Mol. Biol. 27, 333\u2013341 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"77043_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.molcel.2018.02.004","volume":"69","author":"TP Dao","year":"2018","unstructured":"Dao, T. P. et al. Ubiquitin modulates liquid-liquid phase separation of UBQLN2 via disruption of multivalent interactions. Mol. Cell 69, 965\u2013978.e966 (2018).","journal-title":"Mol. Cell"},{"key":"77043_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s41418-021-00913-w","volume":"29","author":"Q Shi","year":"2022","unstructured":"Shi, Q. et al. SPOP mutations promote p62\/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer. Cell Death Differ. 29, 1228\u20131239 (2022).","journal-title":"Cell Death Differ."},{"key":"77043_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0960-9822(01)00369-4","volume":"11","author":"C Belham","year":"2001","unstructured":"Belham, C., Comb, M. J. & Avruch, J. Identification of the NIMA family kinases NEK6\/7 as regulators of the p70 ribosomal S6 kinase. Curr. Biol. 11, 1155\u20131167 (2001).","journal-title":"Curr. Biol."},{"key":"77043_CR25","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1021\/pr500437x","volume":"13","author":"EE de Souza","year":"2014","unstructured":"de Souza, E. E. et al. Characterization of the human NEK7 interactome suggests catalytic and regulatory properties distinct from those of NEK6. J. Proteome Res. 13, 4074\u20134090 (2014).","journal-title":"J. Proteome Res."},{"key":"77043_CR26","first-page":"4423","volume":"125","author":"AM Fry","year":"2012","unstructured":"Fry, A. M., O\u2019Regan, L., Sabir, S. R. & Bayliss, R. Cell cycle regulation by the NEK family of protein kinases. J. Cell Sci. 125, 4423\u20134433 (2012).","journal-title":"J. Cell Sci."},{"key":"77043_CR27","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","volume":"179","author":"DJ Clark","year":"2019","unstructured":"Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964\u2013983.e931 (2019).","journal-title":"Cell"},{"key":"77043_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9771","volume":"6","author":"T Haq","year":"2015","unstructured":"Haq, T. et al. Mechanistic basis of Nek7 activation through Nek9 binding and induced dimerization. Nat. Commun. 6, 8771 (2015).","journal-title":"Nat. Commun."},{"key":"77043_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K. & Kaelin, W. G. Jr Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat. Med. 26, 1519\u20131530 (2020).","journal-title":"Nat. Med."},{"key":"77043_CR30","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s41586-022-04809-8","volume":"606","author":"SA Patel","year":"2022","unstructured":"Patel, S. A. et al. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. Nature 606, 999\u20131006 (2022).","journal-title":"Nature"},{"key":"77043_CR31","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1158\/0008-5472.CAN-19-3870","volume":"80","author":"N Rooney","year":"2020","unstructured":"Rooney, N. et al. RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Res. 80, 2325\u20132339 (2020).","journal-title":"Cancer Res."},{"key":"77043_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216877","volume":"15","author":"C Di Malta","year":"2023","unstructured":"Di Malta, C. et al. TFEB and TFE3 drive kidney cystogenesis and tumorigenesis. EMBO Mol. Med. 15, e16877 (2023).","journal-title":"EMBO Mol. Med."},{"key":"77043_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.eururo.2012.09.052","volume":"63","author":"M Eto","year":"2013","unstructured":"Eto, M. et al. STAT3 polymorphism can predict the response to interferon-alpha therapy in patients with metastatic renal cell carcinoma. Eur. Urol. 63, 745\u2013752 (2013).","journal-title":"Eur. Urol."},{"key":"77043_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1126\/science.aap8411","volume":"361","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361, 290\u2013295 (2018).","journal-title":"Science"},{"key":"77043_CR35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909\u2013918 (2020).","journal-title":"Nat. Med."},{"key":"77043_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"77043_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1039\/C7MD00510E","volume":"9","author":"CI Wells","year":"2018","unstructured":"Wells, C. I., Kapadia, N. R., Counago, R. M. & Drewry, D. H. In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the Nek family of kinases. Medchemcomm 9, 44\u201366 (2018).","journal-title":"Medchemcomm"},{"key":"77043_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani, A. et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol. 29, 789\u2013796 (2011).","journal-title":"J. Clin. Oncol."},{"key":"77043_CR39","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1016\/j.molcel.2021.04.009","volume":"81","author":"Q Pan","year":"2021","unstructured":"Pan, Q. et al. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. Mol. Cell 81, 2736\u20132751.e2738 (2021).","journal-title":"Mol. Cell"},{"key":"77043_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Prim. 3, 17009 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"77043_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","volume":"75","author":"AA Lalani","year":"2019","unstructured":"Lalani, A. A. et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions. Eur. Urol. 75, 100\u2013110 (2019).","journal-title":"Eur. Urol."},{"key":"77043_CR42","doi-asserted-by":"crossref","unstructured":"Bedke J. et al. The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care. Eur. Urol. 80, 393\u2013397 (2021).","DOI":"10.1016\/j.eururo.2021.04.042"},{"key":"77043_CR43","first-page":"283","volume":"36","author":"F Lin","year":"2006","unstructured":"Lin, F. et al. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann. Clin. Lab. Sci. 36, 283\u2013293 (2006).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"77043_CR44","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/s41416-024-02597-8","volume":"130","author":"D Moldvai","year":"2024","unstructured":"Moldvai, D. et al. Tumorigenic role of tacrolimus through mTORC1\/C2 activation in post-transplant renal cell carcinomas. Br. J. Cancer 130, 1119\u20131130 (2024).","journal-title":"Br. J. Cancer"},{"key":"77043_CR45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai, L. et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498\u2013511.e417 (2019).","journal-title":"Cancer Cell"},{"key":"77043_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00998-z","volume":"13","author":"LY El Khoury","year":"2021","unstructured":"El Khoury, L. Y. et al. Identification of DNA methylation signatures associated with poor outcome in lower-risk stage, size, grade and necrosis (SSIGN) score clear cell renal cell cancer. Clin. Epigenetics 13, 12 (2021).","journal-title":"Clin. Epigenetics"},{"key":"77043_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54978-5","volume":"15","author":"Q Ye","year":"2024","unstructured":"Ye, Q. et al. DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity. Nat. Commun. 15, 10596 (2024).","journal-title":"Nat. Commun."},{"key":"77043_CR48","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-17-0686","volume":"77","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. Loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion. Cancer Res. 77, 6524\u20136537 (2017).","journal-title":"Cancer Res."},{"key":"77043_CR49","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 (2025).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77043-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77043-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77043-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:30:33Z","timestamp":1790479833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77043-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77043"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77043-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10147"}}